A study with a selective intestinal FXR inhibitor, Gly-MCA, demonstrated a reduction of triglyceride accumulation in the liver, decreased blood glucose levels and increased insulin sensitivity in the murine model of obesity (Gonzalez et al., 2016). This evidence concerns the gene NR1H4 and obesity due to melanocortin 4 receptor deficiency.